Display options
Cite
Zhang P, Wang W, Wei Z, et al. xCT expression modulates cisplatin resistance in Tca8113 tongue carcinoma cells. Oncol Lett. 2016;12(1):307-314doi: 10.3892/ol.2016.4571.
Zhang, P., Wang, W., Wei, Z., Xu, L. I., Yang, X., & DU, Y. (2016). xCT expression modulates cisplatin resistance in Tca8113 tongue carcinoma cells. Oncology letters, 12(1), 307-314. https://doi.org/10.3892/ol.2016.4571
Zhang, Peng, et al. "xCT expression modulates cisplatin resistance in Tca8113 tongue carcinoma cells." Oncology letters vol. 12,1 (2016): 307-314. doi: https://doi.org/10.3892/ol.2016.4571
Zhang P, Wang W, Wei Z, Xu LI, Yang X, DU Y. xCT expression modulates cisplatin resistance in Tca8113 tongue carcinoma cells. Oncol Lett. 2016 Jul;12(1):307-314. doi: 10.3892/ol.2016.4571. Epub 2016 May 16. PMID: 27347143; PMCID: PMC4906781.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2016 Jul;12(1):307-314. doi: 10.3892/ol.2016.4571. Epub 2016 May 16.

xCT expression modulates cisplatin resistance in Tca8113 tongue carcinoma cells.

Oncology letters

Peng Zhang, Wei Wang, Zhenhui Wei, L I Xu, Xuanning Yang, Yuanhong DU

Affiliations

  1. Department of Stomatology, No. 463 Hospital of Chinese PLA, Shenyang, Liaoning 110042, P.R. China.

PMID: 27347143 PMCID: PMC4906781 DOI: 10.3892/ol.2016.4571

Abstract

Tongue squamous cell carcinoma (TSCC), which is a subtype of head and neck cancer, is the most common type of oral cancer. Due to its high recurrence rate and chemoresistance, the average survival rate for patients with TSCC remains unsatisfactory. At present, cisplatin (CDDP) is utilized as the first-line treatment for numerous solid neoplasms, including TSCC. CDDP resistance develops in the majority of patients; however, the mechanism of such resistance remains unknown. Therefore, the present study aimed to clarify the mechanism of CDDP resistance and attempted to reduce chemoresistance. The results indicated that CDDP significantly increased expression of xCT, which is the light chain and functional subunit of the glutamate/cysteine transporter system x

Keywords: ATF4; Nrf2; cisplatin; sulfasalazine; tongue carcinoma cells; xCT

References

  1. Chem Biol Interact. 2014 Jan 25;207:58-66 - PubMed
  2. Int J Mol Sci. 2014 Oct 23;15(10):19265-80 - PubMed
  3. Urol Oncol. 2014 Aug;32(6):806-14 - PubMed
  4. Cancer Res. 2001 Nov 1;61(21):7722-6 - PubMed
  5. Br J Cancer. 2002 Oct 21;87(9):933-7 - PubMed
  6. Chin J Cancer. 2013 Nov;32(11):614-8 - PubMed
  7. Biomaterials. 2011 Dec;32(34):9068-76 - PubMed
  8. Tumour Biol. 2014 Nov;35(11):10879-90 - PubMed
  9. Mol Cancer Ther. 2012 Mar;11(3):604-15 - PubMed
  10. J Pharmacol Exp Ther. 2010 Oct;335(1):2-12 - PubMed
  11. Mol Biol Rep. 2013 May;40(5):3807-16 - PubMed
  12. Anal Biochem. 1981 Jul 1;114(2):383-7 - PubMed
  13. Cell Death Differ. 2004 Apr;11(4):381-9 - PubMed
  14. Oncogene. 2006 Jun 8;25(24):3397-407 - PubMed
  15. Life Sci. 2010 Aug 14;87(7-8):240-5 - PubMed
  16. Genes Dev. 1998 Apr 1;12(7):982-95 - PubMed
  17. Nature. 1999 Apr 1;398(6726):422-6 - PubMed
  18. Br J Cancer. 1994 Aug;70(2):190-4 - PubMed
  19. Hepatobiliary Pancreat Dis Int. 2007 Jun;6(3):312-20 - PubMed
  20. Cancer Res. 2001 Aug 15;61(16):6050-4 - PubMed
  21. Oncogene. 2012 Apr 12;31(15):1869-83 - PubMed
  22. Jpn J Clin Oncol. 2015 Jan;45(1):88-95 - PubMed
  23. Int J Clin Exp Pathol. 2014 Mar 15;7(4):1502-13 - PubMed
  24. Biochim Biophys Acta. 2013 May;1830(5):3143-53 - PubMed
  25. Yao Xue Xue Bao. 2012 Nov;47(11):1434-9 - PubMed
  26. Cancer Res. 2003 Dec 15;63(24):8592-5 - PubMed
  27. Neurosurgery. 2013 Jan;72 (1):33-41; discussion 41 - PubMed
  28. Int J Oncol. 2013 Jun;42(6):2053-9 - PubMed
  29. Mol Cell Biochem. 2014 May;390(1-2):253-62 - PubMed
  30. Chem Biol Interact. 2012 Apr 15;197(1):58-67 - PubMed
  31. Arch Otolaryngol Head Neck Surg. 2010 May;136(5):493-501 - PubMed
  32. Oncol Rep. 2012 Aug;28(2):749-57 - PubMed
  33. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29 - PubMed
  34. Cancer Res. 2005 Aug 15;65(16):7446-54 - PubMed
  35. Shanghai Kou Qiang Yi Xue. 2001 Mar;10(1):31-4 - PubMed
  36. Leukemia. 2001 Oct;15(10):1633-40 - PubMed
  37. J Biol Chem. 1999 Apr 23;274(17):11455-8 - PubMed
  38. Biomed Res Int. 2014;2014:904341 - PubMed
  39. Cancers (Basel). 2009;1(1):23-38 - PubMed
  40. Br J Cancer. 2003 Mar 24;88(6):951-6 - PubMed
  41. Oncol Rep. 2012 Apr;27(4):1284-91 - PubMed
  42. Mol Cell Biol. 2014 Sep 15;34(18):3421-34 - PubMed
  43. Cancer Sci. 2013 Oct;104(10):1323-9 - PubMed
  44. J Biol Chem. 2000 Dec 15;275(50):39435-43 - PubMed
  45. Cancer Res. 2007 Apr 15;67(8):3878-87 - PubMed
  46. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 - PubMed
  47. Br J Cancer. 2014 May 13;110(10 ):2506-13 - PubMed
  48. Gene. 2014 Apr 1;538(2):342-7 - PubMed
  49. Lancet Oncol. 2006 Jul;7(7):565-74 - PubMed
  50. Mol Cell Biochem. 2012 May;364(1-2):115-29 - PubMed
  51. J Biol Chem. 2003 Mar 14;278(11):9100-6 - PubMed
  52. Nephrol Dial Transplant. 1992;7(1):1-7 - PubMed
  53. Cancer Cell. 2011 Mar 8;19(3):387-400 - PubMed
  54. Nat Med. 2008 Jun;14(6):629-32 - PubMed
  55. Cancer Lett. 2011 Dec 15;312(1):55-61 - PubMed
  56. J Cell Physiol. 2008 Jun;215(3):593-602 - PubMed

Publication Types